355 related articles for article (PubMed ID: 24859340)
21. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract][Full Text] [Related]
22. The immunoprofile of odontogenic keratocyst (keratocystic odontogenic tumor) that includes expression of PTCH, SMO, GLI-1 and bcl-2 is similar to ameloblastoma but different from odontogenic cysts.
Vered M; Peleg O; Taicher S; Buchner A
J Oral Pathol Med; 2009 Aug; 38(7):597-604. PubMed ID: 19473442
[TBL] [Abstract][Full Text] [Related]
23. Expression of Sonic hedgehog (SHH) signaling molecules in ameloblastomas.
Kumamoto H; Ohki K; Ooya K
J Oral Pathol Med; 2004 Mar; 33(3):185-90. PubMed ID: 15128061
[TBL] [Abstract][Full Text] [Related]
24. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
25. Whole Exome Sequencing of
Shimura M; Nakashiro KI; Sawatani Y; Hasegawa T; Kamimura R; Izumi S; Komiyama Y; Fukumoto C; Yagisawa S; Yaguchi E; Hitomi-Koide M; Hyodo T; Uchida D; Kawamata H
In Vivo; 2020; 34(6):3233-3240. PubMed ID: 33144428
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
27. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
28. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
Sharma A; Shah SR; Illum H; Dowell J
Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
[TBL] [Abstract][Full Text] [Related]
30. Differential Profile of Primary and Recurrent Ameloblastomas Among Afro-descendants and Non-Afro-descendants-a Systematic Review.
Patel P; Effiom OA; Akinshipo AO; Akintoye SO
J Racial Ethn Health Disparities; 2024 Feb; 11(1):92-100. PubMed ID: 36596981
[TBL] [Abstract][Full Text] [Related]
31. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
32. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
34. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
35. Targeting oncogenic BRAF in human cancer.
Pratilas CA; Xing F; Solit DB
Curr Top Microbiol Immunol; 2012; 355():83-98. PubMed ID: 21818706
[TBL] [Abstract][Full Text] [Related]
36. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
37. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
38. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
39. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
40. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]